 Trastuzumab: Patients in Treatment Arm A or Treatment Arm B who have FISH HER2 or IHC3 breast cancer will also receive treatment with trastuzumab in addition to their treatment with the combination of bevacizumab with either anastrozole or fulvestrant. Trastuzumab will be administered ONLY to patients with HER2 breast cancer FISH-positive or IHC3. An 8 mgkg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mgkg IV trastuzumab once every 3 weeks. These patients will have the option of receiving their bevacizumab doses at 15 mgkg every 3 weeks rather than 10 mgkg every 2 weeks if they prefer to keep their bevacizumab dosing schedule consistent with their trastuzumab dosing schedule so that the number of visits they must make to the study site is minimized. The dosing schedules for anastrozole for HER2 patients in Treatment Arm A and fulvestrant for HER2 patients in Treatment Arm B will not change. 